{"text": "Subjects underwent 1:1:1 randomization to 0.3 mg or 0.5 mg ranibizumab or sham injections ( Figure 4 ) .Treatment was administered once monthly for three consecutive months , followed by subsequent injections every three months ( quarterly ) in all treatment arms , irrespective of clinical findings .", "label": "", "metadata": {}, "score": "45.507103"}
{"text": "Subjects will be randomized to receive a single set of direct intramuscular injections of either JVS-100 or vehicle control and will be followed for 12 months post dosing .", "label": "", "metadata": {}, "score": "52.444923"}
{"text": "Subjects can receive re - treatment every 4 weeks if there is persistent or recurrent intraretinal , subretinal , or sub - RPE fluid on any OCT modality , or any evidence of hemorrhage on clinical evaluation .", "label": "", "metadata": {}, "score": "52.58256"}
{"text": "If randomized to rilonacept , subjects received this treatment during the first 6 weeks of the study or during the randomized withdrawal ( weeks 15 - 24 ) .", "label": "", "metadata": {}, "score": "53.968178"}
{"text": "Re- treatment after the first six injections will be on an as - needed basis , based on predefined criteria .3.2 RATIONALE FOR STUDY DESIGN .", "label": "", "metadata": {}, "score": "54.353554"}
{"text": "These phases were followed by extended open - label phases .After written informed consent was obtained , subjects who met the protocol eligibility criteria were enrolled at one of 27 study sites in the United States .", "label": "", "metadata": {}, "score": "54.79213"}
{"text": "Uncontrolled blood pressure .Significant hepatic disease .Diabetic subjects with active proliferative retinopathy .Immunodeficient states or subjects receiving chronic immunosuppressive therapy .Pregnant or lactating women or subjects of childbearing potential not protected by an effective method of birth control .", "label": "", "metadata": {}, "score": "55.025482"}
{"text": "Patients can be told that we really do not know the best dosing regimen , but the evidence is strong that less frequent dosing with close follow - up is a viable option .", "label": "", "metadata": {}, "score": "55.638103"}
{"text": "All subjects were then treated with single - blind rilonacept for 9-weeks , followed by a subsequent 9-week , double - blind , withdrawal phase during which subjects were re - randomized to either rilonacept or placebo .", "label": "", "metadata": {}, "score": "56.883713"}
{"text": "Treatment was self administered at the first signs and symptoms of a herpatic lesion .The treatment phase ended after eighty subjects in each group had herpatic recurrence and received treatment .", "label": "", "metadata": {}, "score": "57.938515"}
{"text": "Design : Phase III , randomized , controlled , masked ; patients randomized to receive standard of care ( macular grid laser or observation ) or either a 0.5 mg or a 2 mg Retisert implant ; enrollment of patients for the 2 mg dose discontinued early on Cold Sores ( Herpes Labialis Infections ) .", "label": "", "metadata": {}, "score": "58.2759"}
{"text": "Some subjects were treated with Placebo in the Study .This occurred ( if subject randomized to Placebo ) either during the first 6 weeks of the study or during the randomized withdrawal ( weeks 15 - 24 ) .", "label": "", "metadata": {}, "score": "58.656906"}
{"text": "Cohort A - Subjects can receive re - treatment every 4 weeks if there is persistent or recurrent intraretinal , subretinal , or sub - RPE fluid on any OCT modality , or any evidence of hemorrhage on clinical evaluation .", "label": "", "metadata": {}, "score": "58.77814"}
{"text": "However , while monthly dosing for two years might be excessive , inadequate dosing and follow - up can be detrimental to our patients and must be avoided .", "label": "", "metadata": {}, "score": "59.13584"}
{"text": "Patients were randomized 1:1:1 to receive 0.3 mg or 0.5 mg ranibizumab quarterly or 0.3 mg ranibizumab monthly ( Figure 7 ) .In all treatment groups , patients received three consecutive monthly ranibizumab injections followed by either monthly or quarterly injections ( every three months ) for the remainder of the year .", "label": "", "metadata": {}, "score": "60.095882"}
{"text": "Subjects will be randomized to receive either 8 mg of JVS-100 or placebo over 16 injections .Intervention : Biological : JVS-100(8 mg ) or placebo/16 injections .", "label": "", "metadata": {}, "score": "60.583412"}
{"text": "Patients receiving immunosuppressive agents ( including but not limited to cyclosporine , methotrexate , azathioprine , mycophenolate mofetil and systemic steroids ) are excluded from the screening visit until study completion .", "label": "", "metadata": {}, "score": "60.61606"}
{"text": "Subjects will be randomized to receive either 16 mg of JVS-100 or placebo over 16 injections .Intervention : Biological : JVS-100(16 mg ) or placebo/16 injections .", "label": "", "metadata": {}, "score": "60.884388"}
{"text": "After three monthly doses , patients returned at month three and then every three months thereafter for treatment based on a set of criteria that relied heavily on visual acuity testing and OCT imaging .", "label": "", "metadata": {}, "score": "61.29513"}
{"text": "Patients were given an initial single treatment of PhotoPoint SnET2 or placebo followed by a low power light treatment .Patients followed for 2 years and re - treated if required .", "label": "", "metadata": {}, "score": "61.331932"}
{"text": "Subjects will be randomized to receive either 8 mg of JVS-100 or placebo over 8 injections .Intervention : Biological : JVS-100(8 mg ) or placebo/8 injections .", "label": "", "metadata": {}, "score": "61.539154"}
{"text": "Subjects , subject 's parents or legal guardians that are able to comply with all study procedures ; .Willingness to allow for serum samples to be stored beyond the study period , for potential additional future testing to better characterize immune response .", "label": "", "metadata": {}, "score": "62.588997"}
{"text": "Subjects , subject 's parents or legal guardians that are able to comply with all study procedures ; .Willingness to allow for serum samples to be stored beyond the study period , for potential additional future testing to better characterize immune response .", "label": "", "metadata": {}, "score": "62.588997"}
{"text": "It was designed to demonstrate a clear relationship between the rPA102 dose administered and the subsequent immune response .Safety data were positive with no serious adverse events or toxicities reported .", "label": "", "metadata": {}, "score": "62.80162"}
{"text": "Patients will be given a single intravitreal injection of drug or placebo and allows for up to two additional consecutive daily injections for patients who show signs of improvement following the previous injection .", "label": "", "metadata": {}, "score": "63.33985"}
{"text": "At week 15 , subjects were re - randomized in a 1:1 ratio between Placebo and rilonacept 160 mg .Subjects baseline period was the 21-day period prior to week 15 randomization .", "label": "", "metadata": {}, "score": "63.372185"}
{"text": "In part A , a negative change in mean values indicated improvement under treatment with rilonacept in symptoms .The DHAF was used because it is a validated instrument to collect subject 's self - reported responses .", "label": "", "metadata": {}, "score": "63.720516"}
{"text": "Purpose : To evaluate efficacy in clearing hemorrhage .Design : 2 Phase III studies : prospective , randomized , parallel , placebo - controlled , double - masked ; patients assigned to control group ( saline injection ) or test group ( 7.5 IU , 55 IU international unit , or 75 IU international unit injection of Vitase ) .", "label": "", "metadata": {}, "score": "64.119705"}
{"text": "In addition , if the subject is currently receiving antibiotics , antivirals , or antifungals for an infection or for suppression or prophylaxis for any diagnosis .", "label": "", "metadata": {}, "score": "64.12939"}
{"text": "A Phase II , Randomized , Double - Blind , Placebo Controlled Dose Escalation Study to Evaluate the Safety and Efficacy of JVS-100 Administered by Direct Intramuscular Injection to Cohorts of Adults With Critical Limb Ischemia .", "label": "", "metadata": {}, "score": "64.25325"}
{"text": "Subjects in cohort 1 were randomized 1:1 to receive either 0.3 mg ranibizumab or 0.5 mg ranibizumab .cohort 2 received the 0.5 mg dose of ranibizumab .", "label": "", "metadata": {}, "score": "64.42703"}
{"text": "Inclusion / Exclusion Criteria : Vitreous hemorrhage present for at least 1 month ; BCVA of less than 20/200 at initial screening .Purpose : To evaluate the safety and efficacy of single - dose injection to cause a detachment of the vitreous humor from the retina and the impact on slowing the progression of diabetic retinopathy over a 1-year period .", "label": "", "metadata": {}, "score": "64.719444"}
{"text": "Experimental : Cohort 1 .Subjects will be randomized to receive either 4 mg of JVS-100 or placebo over 8 injections .Intervention : Biological : JVS-100(4 mg ) or placebo/8 injections .", "label": "", "metadata": {}, "score": "64.87259"}
{"text": "This suggests that three consecutive injections on a monthly basis should be considered when treatment is initiated .Second , the phase 3 trials clearly demonstrated that monthly anti - VEGF dosing provided a sustained visual acuity benefit and serves as our current gold standard .", "label": "", "metadata": {}, "score": "65.0002"}
{"text": "At 48 months , 4 subjects were available and 3 out of the 4 had antisense RNA present and at month 60 it was present in 1 out of the 3 subjects .", "label": "", "metadata": {}, "score": "65.10033"}
{"text": "Amendments 4 and 6 allowed eligible adult and pediatric subjects aged 7 and above to enroll directly into the open - label phases of the trial .", "label": "", "metadata": {}, "score": "65.21972"}
{"text": "The trial met the primary endpoint of statistical non-inferiority with 85 % of the PULSYS group achieving bacterial eradication versus 83.4 % of the penicillin group .", "label": "", "metadata": {}, "score": "65.42294"}
{"text": "Serious adverse events were reported by 27 % of the TMC125 group and 18 % of the control group .Efficacy data revealed that mean change from baseline in viral load at week 48 for the TMC125 400 mg and 800 mg bid and active control groups was -0.88 , -1.01 and -0.14 log10 copies / ml , respectively .", "label": "", "metadata": {}, "score": "65.49544"}
{"text": "The subjects were randomized to receive subcutaneous ( SC ) injections of placebo or golimumab ( 50 or 100 mg ) at weeks zero , four , eight , twelve , sixteen and twenty .", "label": "", "metadata": {}, "score": "65.561295"}
{"text": "This trial will be performed at multiple study sites in a population of healthy children and adolescent .Subjects will be randomized to receive 2 IM injections of low dose of antigen & adjuvant , or high dose of antigen & adjuvant , or high dose of antigen , according to the study groups .", "label": "", "metadata": {}, "score": "65.69353"}
{"text": "This trial will be performed at multiple study sites in a population of healthy children and adolescent .Subjects will be randomized to receive 2 IM injections of low dose of antigen & adjuvant , or high dose of antigen & adjuvant , or high dose of antigen , according to the study groups .", "label": "", "metadata": {}, "score": "65.69353"}
{"text": "Individuals who have received blood , blood products and/or plasma derivatives or any parenteral immunoglobulin preparation in the past 12 weeks ; .History of progressive or severe neurologic disorder ; .", "label": "", "metadata": {}, "score": "66.14709"}
{"text": "Individuals who have received blood , blood products and/or plasma derivatives or any parenteral immunoglobulin preparation in the past 12 weeks ; .History of progressive or severe neurologic disorder ; .", "label": "", "metadata": {}, "score": "66.14709"}
{"text": "This is an open - label , Phase I / II study of intravitreally administered 2.0 mg ranibizumab in subjects with persistent fluid or recurrent fluid on OCT after having received at least nine ranibizumab injections in the past twelve months .", "label": "", "metadata": {}, "score": "66.3531"}
{"text": "Participation in another clinical trial in the last 30 days .Clinically significant elevations in PT / PTT / INR .History of drug or alcohol abuse in the last year .", "label": "", "metadata": {}, "score": "66.39589"}
{"text": "No .Contacts ICMJE .Contact information is only displayed when the study is recruiting subjects Allocation : Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Parallel Assignment Masking : Open Label Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "66.439735"}
{"text": "Had documented mutation in NLRP-3 ( Cold Induced Autoinflammatory Syndrome-1 or CIAS1 ) in subject or relative , and willingness to have a confirmatory genetic ( Deoxyribonucleic acid or DNA ) test ( cheek swab ) .", "label": "", "metadata": {}, "score": "66.47996"}
{"text": "10 In this study , all patients were rolled over into active treatment with ranibizumab , but treatment was at the discretion of the investigator .", "label": "", "metadata": {}, "score": "66.59848"}
{"text": "Phase III studies of patients with primary or recurrent choroidal neovascularization ( CNV ) secondary to age - related macular degeneration ( AMD ) treated with repeated intravitreal injections of 0.5 mg of ranibizumab showed evidence for bioactivity , safety , and tolerability ( Rosenfeld 2006 ) ; .", "label": "", "metadata": {}, "score": "66.63634"}
{"text": "Novartis has issued results of a phase III study of secukinumab for psoriatic arthritis ( PsA ) .FUTURE 1 was a first multicenter , randomized , placebo - controlled study evaluating the efficacy and safety of secukinumab in PsA. In the study , patients received an intravenous loading dose every two weeks for the first four weeks of treatment followed by monthly subcutaneous doses of 75 mg or 150 mg compared to placebo .", "label": "", "metadata": {}, "score": "66.63767"}
{"text": "Prior treatment with full or half fluence verteporfin PDT .Previous intravitreal drug delivery ( e.g. , intravitreal corticosteroid injection , anti - angiogenic drugs besides ranibizumab , or device implantation ) in the study eye within the last 12 months .", "label": "", "metadata": {}, "score": "67.75206"}
{"text": "Design : Phase II , randomized , double - masked , controlled study ; two dose levels once weekly for 4 weeks , followed by maintenance doses once every 4 weeks through week 48 .", "label": "", "metadata": {}, "score": "67.784805"}
{"text": "Subject accrual into the trial is expected to be completed within 6 months .All subjects will be evaluated monthly with a full ocular examination , visual acuity measurement ( ETDRS chart at distance of 4 meters ) , OCT , and adverse event monitoring .", "label": "", "metadata": {}, "score": "67.98013"}
{"text": "The drug was well tolerated .The most frequent adverse events were nausea , diarrhea and headache .Based on this data , Celgene expects to file a separate NDA in the U.S. for psoriasis and a combined PsA / psoriasis MAA submission in Europe in the second half of 2013 .", "label": "", "metadata": {}, "score": "68.18912"}
{"text": "Status : New Drug Application submitted to FDA on March 31 .Priority Review designation .Purpose : To determine the safety and efficacy of SnET2 in patients with subfoveal CNV secondary to AMD .", "label": "", "metadata": {}, "score": "68.4791"}
{"text": "Experimental : high dose of antigen .Biological : Monovalent A / H1N1 influenza vaccine .This trial will be performed at multiple study sites in a population of healthy children and adolescent .", "label": "", "metadata": {}, "score": "68.67488"}
{"text": "Experimental : high dose of antigen .Biological : Monovalent A / H1N1 influenza vaccine .This trial will be performed at multiple study sites in a population of healthy children and adolescent .", "label": "", "metadata": {}, "score": "68.67488"}
{"text": "Janssen issued results from a phase III trial of STELARA ( ustekinumab ) for active psoriatic arthritis .Patients were na\u00efve to treatment with anti - TNF - alpha therapies and/or IL-12/23 inhibitors .", "label": "", "metadata": {}, "score": "68.715416"}
{"text": "Drug : Ranibizumab .Intravitreal Injection of 2.0 mg formulation .Other Name : Lucentis .Active Comparator : 6 Week Re - treatment .Subjects can receive re - treatment every 6 weeks if there is persistent or recurrent intraretinal , subretinal , or sub - RPE fluid on any OCT modality , or any evidence of hemorrhage on clinical evaluation .", "label": "", "metadata": {}, "score": "68.79025"}
{"text": "This is in comparison to 17.3 % and 15.3 % of placebo patients who achieved ACR20 , respectively .Secukinumab was well - tolerated in both studies .", "label": "", "metadata": {}, "score": "69.07726"}
{"text": "Presence of any other condition that , in the opinion of the investigator , might compromise any aspect of the trial .Acute coronary syndrome within 3 month prior to enrollment .", "label": "", "metadata": {}, "score": "69.217285"}
{"text": "NYHA Class IV heart failure .Evidence of osteomyelitis or active infection .Subjects with Buerger 's Disease .Subjects with a history of Systemic Lupus Erythematosus ( SLE ) flare .", "label": "", "metadata": {}, "score": "69.24159"}
{"text": "The secondary objectives were as follows : .To determine the safety and tolerability of rilonacept in subjects with CAPS .To assess the effect of rilonacept on laboratory measures of inflammation such as acute phase reactants .", "label": "", "metadata": {}, "score": "69.44847"}
{"text": "Open - Label rilonacept 160 mg .After week 24 ( the end of part B ) , all subjects went into weekly dosing of open label rilonacept 160 mg .", "label": "", "metadata": {}, "score": "69.52794"}
{"text": "Dosing should not occur earlier than 22 days after the previous treatment .Study visits should be scheduled to occur every 30 ( \u00b17 ) days relative to the date of the first injection ( Day 0 ) .", "label": "", "metadata": {}, "score": "69.56202"}
{"text": "RP .REFERENCES .Gragoudas ES , Adamis AP , Cunningham ET , Jr. , Feinsod M , Guyer DR .Pegaptanib for neovascular age - related macular degeneration .", "label": "", "metadata": {}, "score": "69.69212"}
{"text": "Any CNVM lesion ( Occult , Minimally Classic or Classic ) ( i.e. , leakage on fluorescein angiography or subretinal , intraretinal , or sub - RPE fluid on Spectral Domain OCT ) secondary to age - related macular degeneration .", "label": "", "metadata": {}, "score": "69.92518"}
{"text": "Study drug is administered as a 2.0 mL subcutaneous injection once a week .Drug : rilonacept 160 mg .Rilonacept was given by subcutaneous injection .", "label": "", "metadata": {}, "score": "70.57124"}
{"text": "This is an open - label , study of 0.5 mg intravitreal dose of Ranibizumab in combination with 1 mg / kg / wk subcutaneous dose of Efalizumab in in subjects with AMD .", "label": "", "metadata": {}, "score": "70.67085"}
{"text": "Additional phase III trials are ongoing at this time .Sponsor : Alcon Research , Ltd. .Status : Enrollment is ongoing .Purpose : To demonstrate that anecortave acetate ( 15 mg or 30 mg ) is safe and effective in arresting the progression of nonexudative AMD in patients who are at risk for progressing to exudative AMD .", "label": "", "metadata": {}, "score": "70.750465"}
{"text": "A Phase I / II Open Label , Multicenter Study of the Safety , Tolerability and Efficacy of Multiple Intravitreal Injections of ( Super - dose Anti - VEgf SAVE Trial ) 2.0 mg Ranibizumab in Subjects With Chronic Fluid on OCT Post Multiple Injections With Ranibizumab .", "label": "", "metadata": {}, "score": "70.843704"}
{"text": "Number of Patients : 720 .Study : An evaluation of efficacy and safety of posterior juxtascleral injections of anecortave acetate 15 mg ( 0.5 ml of 30 mg / ml anecortave acetate sterile suspension ) versus Visudyne in patients with subfoveal exudative AMD eligible for initial treatment with photodynamic therapy using Visudyne ( C-01 - 99 ) .", "label": "", "metadata": {}, "score": "70.862045"}
{"text": "Safety continued after that timepoint until the end of the study .Double - blind phases : adults age 18 and above ; Open - label extension : Adults and children aged 7 years and older .", "label": "", "metadata": {}, "score": "71.09166"}
{"text": "Not Provided .Eligibility Criteria ICMJE .Inclusion Criteria : .Ability to provide written informed consent and comply with study assessments for the full duration of the study .", "label": "", "metadata": {}, "score": "71.11606"}
{"text": "Women of childbearing potential not using adequate contraception ( as defined in the inclusion criteria ) .History of stroke within the last 3 months of screening visit .", "label": "", "metadata": {}, "score": "71.26799"}
{"text": "Long - term safety data were positive with treatment well tolerated and no adverse events reported .Efficacy data collected demonstrated that the engineered stem cells were able to survive long term in vivo and to produce CD4 + cell progeny containing functioning antisense genes .", "label": "", "metadata": {}, "score": "71.43335"}
{"text": "But this does not mean that patients must be treated monthly to achieve the best possible visual acuity outcomes .It just means that treat - and - ignore is not a viable treatment option .", "label": "", "metadata": {}, "score": "71.5331"}
{"text": "Subcutaneous injection of Placebo occurred during first 6 weeks of the study or during randomized withdrawal ( weeks 15 - 24 ) .On Day 1 , subjects received two placebo injections .", "label": "", "metadata": {}, "score": "71.65515"}
{"text": "Intervention : Drug : Efalizumab , Ranibizumab .Not Provided .Recruitment Status ICMJE .Withdrawn .Enrollment ICMJE .Completion Date .Not Provided .", "label": "", "metadata": {}, "score": "71.68982"}
{"text": "Current or history of prior treatment of psoriasis with subcutaneous efalizumab within 6 months of study entry .Have a history of ongoing uncontrolled serious bacterial , viral , fungal , or atypical mycobacterial infection .", "label": "", "metadata": {}, "score": "71.71513"}
{"text": "Secukinumab was well - tolerated in the study , with a safety profile generally consistent with that observed in the psoriasis clinical trial program .The most common adverse events ( AEs ) for either secukinumab dose were the common cold ( nasopharyngitis , 8.2 % ) , headache ( 5.4 % ) and upper respiratory tract infections ( 5.4 % ) .", "label": "", "metadata": {}, "score": "71.839294"}
{"text": "Number of Patients : 169 .Inclusion / Exclusion Criteria : Eligibility for thermal laser therapy for DME .Sponsor : Control Delivery Systems and Bausch & Lomb Pharmaceuticals .", "label": "", "metadata": {}, "score": "71.88564"}
{"text": "Subjects will go no longer than 12 weeks without treatment .Drug : Ranibizumab .Intravitreal Injection of 2.0 mg formulation .Other Name : Lucentis .", "label": "", "metadata": {}, "score": "71.93045"}
{"text": "From Week 15 to Week 24 ( During the Randomized Withdrawal Phase or Part B )[ Time Frame : Week 15 through Week 24 ( randomized withdrawal ) ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "72.02034"}
{"text": "Study drug is administered as a 2.0 mL subcutaneous injection once a week .At baseline ( week 0 ) subjects receive a loading dose of rilonacept 320 mg .", "label": "", "metadata": {}, "score": "72.15181"}
{"text": "Subject should be on stable therapy for the treatment of CLI , including statin and antiplatelet therapy .Subject must be willing to forgo treatment with hyperbaric oxygen , nerve stimulation , ot sympathectomy for treatment of CLI 10 days prior to 45 days following injection of study drug .", "label": "", "metadata": {}, "score": "72.2901"}
{"text": "The present study , randomized , single - blind , dose - ranging , multicenter study , will evaluate immunogenicity , safety and tolerability of two doses of adjuvanted and not - adjuvanted new swine - origin influenza A / H1N1 virus monovalent subunit vaccine in healthy children and adolescents .", "label": "", "metadata": {}, "score": "72.32245"}
{"text": "Subjects will receive efalizumab 1mg / kg weekly subcutaneous injections for 24 weeks .Subcutaneous Efalizumab injections can be self administered after an initial teaching session in office on Day 0 .", "label": "", "metadata": {}, "score": "72.389626"}
{"text": "Every 6 weeks regimen will test potential longer duration of action of 2.0 mg ranibizumab .Willingness to provide signed informed consent and Health Insurance Portability and Accountability Act ( HIPAA ) authorization .", "label": "", "metadata": {}, "score": "72.544876"}
{"text": "Changes in visual acuity over 24 months as seen in the PIER trial .This failure to appreciate the need for more frequent dosing was repeated in the subsequent HORIZON , SAILOR and EXCITE studies .", "label": "", "metadata": {}, "score": "72.63928"}
{"text": "UCB issued results from a phase III trial of certolizumab pegol for psoriatic arthritis .This global , 48 week , double - blind , parallel - group trial , RAPID - PsA , enrolled 409 subjects with adult onset active psoriatic arthritis .", "label": "", "metadata": {}, "score": "72.805885"}
{"text": "A Phase I study of patients with uveitis treated with subcutaneous efalizumab injections of 1mg / kg in patients with uveitic macular edema is currently enrolling ( ClinicalTrials.gov Identifier : NCT00280826 ) .", "label": "", "metadata": {}, "score": "72.94136"}
{"text": "A similar trend was witnessed in the previously treated patients .As with the PIER Study , the visual acuity scores improved over the first three monthly doses and then subsequently declined over the ensuing 10 months .", "label": "", "metadata": {}, "score": "72.95127"}
{"text": "Biological : Monovalent A / H1N1 influenza vaccine .This trial will be performed at multiple study sites in a population of healthy children and adolescent .", "label": "", "metadata": {}, "score": "72.96672"}
{"text": "Biological : Monovalent A / H1N1 influenza vaccine .This trial will be performed at multiple study sites in a population of healthy children and adolescent .", "label": "", "metadata": {}, "score": "72.96672"}
{"text": "Moreover , after three monthly doses at the start of the study , the mean visual acuity decreased over the ensuing 10 months , which was not observed in the phase 3 trials with monthly dosing .", "label": "", "metadata": {}, "score": "72.96716"}
{"text": "Based on positive phase III results , Cypress and Forest planned to file an NDA around the end of 2007 .Schering Plough and Centocor reported positive results from a phase III trial of golimumab for the treatment of psoriatic arthritis .", "label": "", "metadata": {}, "score": "73.24094"}
{"text": "Exclusion Criteria : .Pregnancy ( positive pregnancy test ) or lactation Premenopausal women not using adequate contraception .The following are considered effective means of contraception : surgical sterilization or use of oral contraceptives , barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel , an IUD , or contraceptive hormone implant or patch .", "label": "", "metadata": {}, "score": "73.62753"}
{"text": "At week fourteen , 66 % and 67 % of subjects in the golimumab 50 mg and 100 mg arms , respectively , were DAS28 responders , compared with 24 % of subjects in the placebo arm ( p less than 0.001 ) .", "label": "", "metadata": {}, "score": "74.170135"}
{"text": "No loading dose was given for subjects who entered directly into the open - label .Detailed Description : .Primary Objective : .The primary objective of this study was to assess the effect of rilonacept on the clinical signs and symptoms of Cryopyrin - Associated Periodic Syndrome ( CAPS ) when used for chronic therapy as evaluated by the subjects themselves over time using a validated patient - reported outcomes tool .", "label": "", "metadata": {}, "score": "74.189896"}
{"text": "Study Type ICMJE .Interventional .Study Phase .Phase 1 .Study Design ICMJE .Allocation : Non - Randomized Intervention Model : Single Group Assignment Masking : Open Label Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "74.601585"}
{"text": "Participation in another simultaneous medical investigation or trial .Ocular Exclusion Criteria Prior Ocular Treatment .History of vitrectomy surgery , submacular surgery , or other surgical intervention for AMD in the study eye .", "label": "", "metadata": {}, "score": "74.63475"}
{"text": "Any concurrent intraocular condition in the study eye ( e.g. , cataract or diabetic retinopathy ) that , in the opinion of the investigator , could either : .", "label": "", "metadata": {}, "score": "74.88318"}
{"text": "IL1T - AI-0505 : A Multi - center , Double - Blind , Placebo - Controlled Study of the Safety , Tolerability , & Efficacy of Rilonacept in Subjects With Cryopyrin - Associated Periodic Syndromes ( CAPS )", "label": "", "metadata": {}, "score": "75.00612"}
{"text": "A Randomized , Single - blind , Dose - Ranging Study to Evaluate Immunogenicity , Safety and Tolerability of Different Formulations of Adjuvanted and Non Adjuvanted Cell - derived , Inactivated Novel Swine Origin A / H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects From 6 Months to 17 Years of Age .", "label": "", "metadata": {}, "score": "75.14043"}
{"text": "4 Of course , the gold - standard for treatment is the two - year monthly dosing regimen used in the phase 3 clinical trials for ranibizumab ( Figures 2 and 3 ) , which was FDA - approved in 2006 .", "label": "", "metadata": {}, "score": "75.28334"}
{"text": "Treatment was well tolerated , with no reported serious adverse events .Based on the results , Transport plans to initiate the next stage of development in 2008 .", "label": "", "metadata": {}, "score": "75.367195"}
{"text": "Three treatment arms : PDT and sham injection , sham PDT and Lucentis dose A , sham PDT and Lucentis dose B .Number of Patients : 426 .", "label": "", "metadata": {}, "score": "75.42705"}
{"text": "Status : Enrollment is complete .Purpose : To demonstrate that anecortave acetate 15 mg is superior to placebo in maintenance of visual acuity .Design : Phase III , nonrandomized , open - label , uncontrolled , single group , safety / efficacy study .", "label": "", "metadata": {}, "score": "75.43969"}
{"text": "Dr. Rosenfeld can be reached via e - mail at prosenfeld@med.miami.edu .The present study , randomized , single - blind , dose - ranging , multicenter study , will evaluate immunogenicity , safety and tolerability of two doses of adjuvanted and not - adjuvanted new swine - origin influenza A / H1N1 virus monovalent subunit vaccine in healthy children and adolescents .", "label": "", "metadata": {}, "score": "75.62172"}
{"text": "Purpose : Evaluate safety , efficacy and tolerability of 24 monthly intravitreal injections of ranibizumab ( Lucentis ) in preventing vision loss in patients with AMD .", "label": "", "metadata": {}, "score": "75.69763"}
{"text": "Active intraocular inflammation ( grade trace or above ) in the study eye .Current vitreous hemorrhage in the study eye .History of rhegmatogenous retinal detachment or macular hole ( Stage 3 or 4 ) in the study eye .", "label": "", "metadata": {}, "score": "75.713196"}
{"text": "N Engl J Med 2006;355:1419 - 31 .Brown DM , Kaiser PK , Michels M , et al .Ranibizumab versus verteporfin for neovascular age - related macular degeneration .", "label": "", "metadata": {}, "score": "75.76674"}
{"text": "Genentech failed to learn from the failure of the PIER study and perpetuated this flawed study design in both the SAILOR and HORIZON studies .In Europe , Novartis Pharmaceuticals compounded the mistake by running the EXCITE trial .", "label": "", "metadata": {}, "score": "75.84036"}
{"text": "48 subjects diagnosed with Rutherford Class 4 - 5 Critical Limb Ischemia ( CLI ) with non - healing ulcers and/or ischemic rest pain will be enrolled in this study designed to investigate the safety and efficacy of JVS-100 .", "label": "", "metadata": {}, "score": "75.92333"}
{"text": "Assess number of ranibizumab injections in each of the two doses required through Month 12 [ Time Frame : 1 year ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "76.02252"}
{"text": "Both strategies are reasonable .CONCLUSION .By mid-2011 , we should know for sure whether the outcomes from OCT - guided therapy are comparable to monthly dosing based on the results of the ongoing Comparisons of Age - Related Macular Degeneration Treatment Trials .", "label": "", "metadata": {}, "score": "76.42946"}
{"text": "Changes in visual acuity over 24 months as seen in the ANCHOR trial .CLINICAL TRIALS DATA .Retinal physicians are always striving to deliver a treatment benefit while subjecting our patients to the least possible risk and inconvenience .", "label": "", "metadata": {}, "score": "76.56579"}
{"text": "Brown DM , Michels M , Kaiser PK , Heier JS , Sy JP , Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age - related macular degeneration : Two - year results of the ANCHOR study .", "label": "", "metadata": {}, "score": "76.9886"}
{"text": "Rilonacept was given by subcutaneous injection .It was administered weekly at the dose of 160 mg .On Day 1 , subjects received two injections of rilonacept ( for a total of 320 mg ) .", "label": "", "metadata": {}, "score": "77.187904"}
{"text": "A Randomized , Single - blind , Dose - Ranging Study to Evaluate Immunogenicity , Safety and Tolerability of Different Formulations of Adjuvanted and Non Adjuvanted Egg - derived , Inactivated Novel Swine Origin A / H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects From 6 Months to 17 Years of Age .", "label": "", "metadata": {}, "score": "77.25045"}
{"text": "Mitchell P , Korobelnik JF , Lanzetta P , et al .Ranibizumab ( Lucentis ) in neovascular age - related macular degeneration : evidence from clinical trials .", "label": "", "metadata": {}, "score": "77.480255"}
{"text": "Study : denufosol tetrasodium ( INS37217 Ophthalmic ) , P2Y2 receptor agonist for intravitreal injection .Sponsor : Inspire Pharmaceuticals .Purpose : To compare the safety and efficacy of INS37217 Ophthalmic to placebo as a first - line therapy in patients with rhegmatogenous retinal detachment .", "label": "", "metadata": {}, "score": "78.08499"}
{"text": "History of corneal transplant in the study eye .Concurrent Systemic Conditions ( Exclusion ) .If the patient 's blood pressure needs to be controlled by antihypertensive medication , the patient can become eligible if medication is taken continuously for at least 30 days prior to Day 0 .", "label": "", "metadata": {}, "score": "78.12106"}
{"text": "Best corrected visual acuity in the study eye between 20/40 and 20/320 .Subfoveal choroidal neovascularization , secondary to age related macular degeneration .6 - 10 anti - VEGF treatments allowed prior to enrollment .", "label": "", "metadata": {}, "score": "78.1642"}
{"text": "Based on these results , Advancis expected to file a NDA for once - daily Amoxicillin by late 2006 or early 2007 .Enzo Biochem issued positive long term results from a phase I trial , initiated in January of 2001 , of HGTV43 for the treatment of HIV .", "label": "", "metadata": {}, "score": "78.17883"}
{"text": "Inability to obtain fundus photographs or fluorescein angiograms of sufficient quality to be analyzed and graded by the central reading center .Inability to comply with study or follow - up procedures .", "label": "", "metadata": {}, "score": "78.19922"}
{"text": "Both .Ages .40 Years and older .Accepts Healthy Volunteers .No .Contacts ICMJE .Contact information is only displayed when the study is recruiting subjects Psoriatic Arthritis .", "label": "", "metadata": {}, "score": "78.24786"}
{"text": "The mean change in VA from baseline was measured at 4.0 , 2.8 , 8.0 letters in the 0.3 mg quarterly , 0.5 quarterly and 0.3 mg monthly groups , respectively ( Figure 8 ) .", "label": "", "metadata": {}, "score": "78.43532"}
{"text": "Please refer to this study by its ClinicalTrials.gov identifier : NCT00288704 Current Primary Outcome Measures ICMJE ( submitted : August 4 , 2011 ) .To Investigate the safety and tolerability of escalating doses of JVS-100 delivered via direct intramuscular injections to subjects with CLI .", "label": "", "metadata": {}, "score": "78.56593"}
{"text": "This is a double - blind , placebo controlled study designed to evaluate the safety and efficacy of JVS-100 given to adult subjects with critical limb ischemia ( CLI ) .", "label": "", "metadata": {}, "score": "78.66971"}
{"text": "Rosenfeld PJ , Moshfeghi AA , Puliafito CA .Optical coherence tomography findings after an intravitreal injection of bevacizumab ( Avastin ) for neovascular age - related macular degeneration .", "label": "", "metadata": {}, "score": "78.89545"}
{"text": "Only one eye will be enrolled in the Study .If both eyes are eligible study investigator will select the eye for entry .The total area of subretinal hemorrhage and fibrosis must comprise less than 50 % of the total lesion .", "label": "", "metadata": {}, "score": "78.97296"}
{"text": "IL-1 Trap ( rilonacept ) was designed to bind to the interleukin-1 cytokine and prevent it from binding to its receptors in the body .Allocation : Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Parallel Assignment Masking : Double Blind ( Subject , Caregiver , Investigator , Outcomes Assessor ) Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "79.12346"}
{"text": "Purpose : To demonstrate that anecortave acetate 15 mg is equal to or better than PDT with Visudyne after 12 months of treatment in patients eligible for initial PDT treatment .", "label": "", "metadata": {}, "score": "79.23927"}
{"text": "Data demonstrated a clinically relevant and statistically significant improvement at week 12 in the signs and symptoms of psoriatic arthritis .The treatment was well tolerated and adverse events were consistent with those seen in other trials of certolizumab pegol .", "label": "", "metadata": {}, "score": "79.23969"}
{"text": "Changes in visual acuity over 12 months as seen in the HORIZON trial .Prior to FDA approval of ranibizumab , Genentech offered early access to ranibizumab within a clinical study known as SAILOR .", "label": "", "metadata": {}, "score": "79.54358"}
{"text": "Original Secondary Outcome Measures ICMJE .Same as current .Current Other Outcome Measures ICMJE .Not Provided .Original Other Outcome Measures ICMJE .Not Provided .", "label": "", "metadata": {}, "score": "79.58325"}
{"text": "While the PrONTO study was under way , Genentech designed a clinical trial known as the PIER study in an attempt to use fixed dosing intervals longer than one month rather than use OCT - guided therapy as the basis for retreatment .", "label": "", "metadata": {}, "score": "79.60921"}
{"text": "Site(s ) : 117 .Inclusion / Exclusion Criteria : Any subtype of CNV ; visual acuity 20/40 to 20/320 ; lesion size 12 disc areas or less .", "label": "", "metadata": {}, "score": "79.65288"}
{"text": "Fast Track designation .Dermatologic and Ophthalmic Drugs Advisory Committee review on August 27 .Purpose : To establish the safety and efficacy of intravitreal injections of pegaptanib sodium in patients with exudative AMD .", "label": "", "metadata": {}, "score": "79.78311"}
{"text": "Premenopausal women not using adequate contraception .The following are considered effective means of contraception : surgical sterilization or use of oral contraceptives , barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel , an IUD , or contraceptive hormone implant or patch .", "label": "", "metadata": {}, "score": "79.81207"}
{"text": "Presence of fibrosis , hemorrhage , serous pigment epithelial detachments , tear ( rip ) of the retinal pigment epithelium or other hypofluorescent lesions should not obscure greater than 50 % of the CNV lesion .", "label": "", "metadata": {}, "score": "79.905266"}
{"text": "Lalwani GA , Rosenfeld PJ , Fung AE , et al .A variable - dosing regimen with intravitreal ranibizumab for neovascular age - related macular degeneration : year 2 of the PrONTO Study .", "label": "", "metadata": {}, "score": "79.90532"}
{"text": "History of any anaphylaxis , serious vaccine reactions to any excipients and to eggs ( including ovalbumin ) and chicken protein ; .Individuals who have had adjuvanted influenza vaccine or documented confirmed or suspected influenza disease within 3 months prior to Day 1 .", "label": "", "metadata": {}, "score": "79.95695"}
{"text": "History of any anaphylaxis , serious vaccine reactions to any excipients and to eggs ( including ovalbumin ) and chicken protein ; .Individuals who have had adjuvanted influenza vaccine or documented confirmed or suspected influenza disease within 3 months prior to Day 1 .", "label": "", "metadata": {}, "score": "79.95695"}
{"text": "Humanization of MHM24 was accomplished by grafting the murine complementarity determining regions ( hypervariable region ) into consensus human IgG1/ heavy and light chain sequences ( Werther et al 1996 ) .", "label": "", "metadata": {}, "score": "80.00377"}
{"text": "In study FMS-031 there were 488 evaluable subjects for the fibromyalgia syndrome analysis and 491 evaluable subjects for the fibromyalgia pain analysis .A statistically significant number of subjects treated with milnacipran during Study MLN - MD-02 met the composite syndrome responder criteria : 25 % and 26 % for the milnacipran 100 mg and 200 mg groups compared to 13 % for placebo .", "label": "", "metadata": {}, "score": "80.08884"}
{"text": "Design : Phase II , randomized , double - blind , placebo - control , parallel assignment .Number of Patients : 90 .Purpose : To compare the safety and efficacy of pegaptanib with placebo in patients with diabetic macular edema .", "label": "", "metadata": {}, "score": "80.26042"}
{"text": "Not surprisingly , the average visual acuity decreased over the subsequent year when patients were ignored .At the Bascom Palmer Eye Institute , we continued to follow our patients monthly , and none of our 37 patients experienced a decrease in their visual acuity ( Figure 6 ) .", "label": "", "metadata": {}, "score": "80.3743"}
{"text": "Study Type ICMJE .Interventional .Study Phase .Phase 2 .Study Design ICMJE .Allocation : Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Parallel Assignment Masking : Double Blind ( Subject , Caregiver , Investigator , Outcomes Assessor ) Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "80.58158"}
{"text": "In 2005 , bevacizumab was first used off - label 2 and was rapidly adopted worldwide , and retina specialists adopted a variety of dosing regimens into their clinical practices .", "label": "", "metadata": {}, "score": "80.629005"}
{"text": "Rosenfeld PJ , Rich RM , Lalwani GA .Ranibizumab : Phase III clinical trial results .Ophthalmol Clin North Am 2006;19:361 - 72 .Boyer DS , Heier JS , Brown DM , Francom SF , Ianchulev T , Rubio RG .", "label": "", "metadata": {}, "score": "80.67354"}
{"text": "[ Time Frame : 1 year ] [ Designated as safety issue : No ] .Evaluate mean change in central retinal thickness over time through Month12 as assessed by all three OCTs ( Stratus , Cirrus , and Spectralis )", "label": "", "metadata": {}, "score": "80.83054"}
{"text": "For general information , see Learn About Clinical Studies .Please refer to this study by its ClinicalTrials.gov identifier : NCT00971542 Current Primary Outcome Measures ICMJE ( submitted : July 29 , 2008 ) .", "label": "", "metadata": {}, "score": "81.07674"}
{"text": "Inclusion / Exclusion Criteria : Patients at least 50 years of age , any race and either sex with exudative AMD who qualified for PDT treatment with Visudyne .", "label": "", "metadata": {}, "score": "81.153"}
{"text": "At week twenty - four , PASI 75 improved to 56 % and 66 % ( golimumab 50 mg and 100 mg , respectively ) compared with 1 % for placebo ( p less than 0.001 ) .", "label": "", "metadata": {}, "score": "81.48086"}
{"text": "If female , was not currently pregnant and was willing to use contraception during the study .Exclusion Criteria : .Had evidence of untreated tuberculosis or other conditions / therapies that made the subject inappropriate for this study .", "label": "", "metadata": {}, "score": "81.52762"}
{"text": "Determine percentage of patients who experience a loss of 15 or more letters from Baseline to Month 12 and Month 12 in ETDRS BCVA [ Time Frame : 1 year ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "81.77138"}
{"text": "Although no birth control method is 100 % effective , the following are considered effective means of contraception : surgical sterilization , use of oral contraceptives , barrier contraception using either a condom or diaphragm with spermicidal gel , an intrauterine device , or contraceptive hormone implant or patch .", "label": "", "metadata": {}, "score": "81.838165"}
{"text": "For general information , see Learn About Clinical Studies .Please refer to this study by its ClinicalTrials.gov identifier : NCT00971100", "label": "", "metadata": {}, "score": "81.918594"}
{"text": "Inclusion Criteria : .Men and women 40 years of age or older .Rutherford Category 4 or 5 .Ankle systolic pressure of 70mmHg or less , or toe pressure of 50mmHg or less .", "label": "", "metadata": {}, "score": "82.016846"}
{"text": "Treatment was generally well tolerated .November 19 , 2007 .Cypress and Forest issued positive composite responder results two phase III trials of milnacipran for the treatment of fibromyalgia .", "label": "", "metadata": {}, "score": "82.10398"}
{"text": "Allocation : Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Parallel Assignment Masking : Single Blind ( Subject ) Primary Purpose : Prevention .", "label": "", "metadata": {}, "score": "82.31578"}
{"text": "Have the presence or history of malignancy , including lymphoproliferative disorders .Subjects with a history of fully resolved basal or squamous cell skin cancer may be enrolled .", "label": "", "metadata": {}, "score": "82.43164"}
{"text": "Regillo CD , Brown DM , Abraham P , et al .Randomized , double - masked , sham - controlled trial of ranibizumab for neovascular age - related macular degeneration : PIER Study year 1 .", "label": "", "metadata": {}, "score": "82.49714"}
{"text": "Life expectancy of less than 1 year .Previous major amputation of the leg to be treated or planned major amputation within the first month following enrollment .", "label": "", "metadata": {}, "score": "82.6911"}
{"text": "Transport Pharmaceuticals announced positive results from a phase IIb trial of device - enhanced acyclovir for the treatment of herpes labialis .This multi - center , randomized , double blind , placebo - controlled , clinic initiated , proof - of - concept trial enrolled 200 non - immunocompromised subjects , aged 18 - 75 years , with histories of recurrent cold sore outbreaks ( 3 or more annually ) .", "label": "", "metadata": {}, "score": "82.76697"}
{"text": "Advancis Pharmaceutical announced positive results from a phase III trial of Amoxicillin , for the treatment of pharyngitis / tonsillitis due to Group A streptococcal infections .", "label": "", "metadata": {}, "score": "82.86015"}
{"text": "These improvements were maintained through week twenty - four , with 52 % and 61 % of subjects receiving golimumab 50 mg and golimumab 100 mg , respectively , reaching ACR 20 , compared with 12 % of subjects receiving placebo ( p less than 0.001 ) .", "label": "", "metadata": {}, "score": "82.8846"}
{"text": "Has received investigational therapy within 60 days prior to study entry .Patients with significantly compromised visual acuity in the study eye due to concomitant ocular conditions .", "label": "", "metadata": {}, "score": "83.22595"}
{"text": "Aphakia or absence of the posterior capsule in the study eye .Intraocular surgery ( including cataract surgery ) in the study eye within 2 months preceding Day 0 .", "label": "", "metadata": {}, "score": "83.49051"}
{"text": "4 mg of JVS-100 or placebo delivered in 8 injections .Biological : JVS-100(8 mg ) or placebo/8 injections .8 mg of JVS-100 or placebo delivered in 8 injections .", "label": "", "metadata": {}, "score": "83.51332"}
{"text": "For general information , see Learn About Clinical Studies .Please refer to this study by its ClinicalTrials.gov identifier : NCT01025232 \" Treat and Ignore \" : The Perils of Anti - VEGF Dosing .", "label": "", "metadata": {}, "score": "83.67877"}
{"text": "Subfoveal fibrosis or atrophy in the study eye .CNV in either eye due to other causes , such as ocular histoplasmosis , trauma , or pathologic myopia Concurrent Ocular Conditions .", "label": "", "metadata": {}, "score": "83.813805"}
{"text": "The composite pain responder criteria for fibromyalgia pain also reached statistical significance during Study MLN - MD-02 : 39 % and 46 % in the milnacipran 100 mg and 200 mg groups , respectively compared to 25 % for placebo .", "label": "", "metadata": {}, "score": "83.84599"}
{"text": "Celgene released positive results from a phase II trial of apremilast for the treatment of psoriatic arthritis .This multi - center , randomized , double - blind , placebo - controlled , three - arm study enrolled 204 subjects who received apremilast 20 mg twice per day , apremilast 40 mg once per day or placebo for 12 weeks .", "label": "", "metadata": {}, "score": "83.904236"}
{"text": "To evaluate immunogenicity against A / California H1N1sw strain after booster dose of egg - derived seasonal trivalent , MF59 adjuvanted vaccine Fluad , recommended for 2010/2011 season , administered 12 months after primary course according to CHMP criteria .", "label": "", "metadata": {}, "score": "84.00207"}
{"text": "To evaluate immunogenicity against A / California H1N1sw strain after booster dose of egg - derived seasonal trivalent , MF59 adjuvanted vaccine Fluad , recommended for 2010/2011 season , administered 12 months after primary course according to CHMP criteria .", "label": "", "metadata": {}, "score": "84.00207"}
{"text": "Safety assessments include tracking of AEs and SAEs and laboratory assessments .Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Critical Limb Ischemia .", "label": "", "metadata": {}, "score": "84.04301"}
{"text": "Inflammatory symptoms of Cryopyrin - Associated Periodic Syndrome ( CAPS ) are due to mutations in a the NLRP-3 gene ( previously known as Cold Induced Autoinflammatory Syndrome-1 or CIAS1 ) .", "label": "", "metadata": {}, "score": "84.15091"}
{"text": "Subject 's parents or legal guardians who are not able to comprehend and to follow all required study procedures ; .Individuals with history or any illness that , in the opinion of the investigator , might interfere with the results of the study or pose additional risk to the subjects due to participation in the study ; .", "label": "", "metadata": {}, "score": "84.36415"}
{"text": "Subject 's parents or legal guardians who are not able to comprehend and to follow all required study procedures ; .Individuals with history or any illness that , in the opinion of the investigator , might interfere with the results of the study or pose additional risk to the subjects due to participation in the study ; .", "label": "", "metadata": {}, "score": "84.36415"}
{"text": "By week 24 , all patients receiving placebo were crossed over to receive STELARA .Improvement in signs and symptoms continued to increase after week 24 , with 55.7 % and 60.3 % of patients in the STELARA 45 mg and STELARA 90 mg groups , respectively , demonstrating ACR 20 response at week 52 .", "label": "", "metadata": {}, "score": "84.43297"}
{"text": "8 mg of JVS-100 or placebo delivered in 16 injections .Biological : JVS-100(16 mg ) or placebo/16 injections .16 mg of JVS-100 or placebo delivered in 16 injections .", "label": "", "metadata": {}, "score": "84.53064"}
{"text": "Changes in visual acuity over 12 months as seen in the EXCITE trial .Although the gains in visual acuity were better than that seen in the PIER and SAILOR studies with quarterly dosed ranibizumab , the EXCITE study clearly demonstrated that quarterly maintenance dosing was inferior to monthly dosing .", "label": "", "metadata": {}, "score": "84.6116"}
{"text": "May 13 , 2013 .Celgene International reported results from a phase III trial of apremilast for the treatment of psoriatic arthritis .This multi - center , double - blind , placebo - controlled , parallel - group study enrolled over 500 patients with psoriatic arthritis .", "label": "", "metadata": {}, "score": "84.615105"}
{"text": "Spaide R. Ranibizumab according to need : a treatment for age - related macular degeneration .Am J Ophthalmol 2007;143:679 - 80 .Rosenfeld PJ , Brown DM , Heier JS , et al .", "label": "", "metadata": {}, "score": "84.66229"}
{"text": "Allocation : Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Parallel Assignment Masking : Single Blind ( Investigator )Primary Purpose : Prevention .", "label": "", "metadata": {}, "score": "84.72319"}
{"text": "Pain composite responders were defined as individuals who achieved both a greater than or equal to 30 % reduction in pain from baseline and who rated themselves as \" very much improved \" or \" much improved \" on a Patient Global Impression of Change ( PGIC ) scale .", "label": "", "metadata": {}, "score": "84.786804"}
{"text": "Study : VEGF inhibition in ocular neovascularization ( VISION ) ( Macugen ) .Sponsor : Eyetech Pharmaceuticals and Pfizer Inc. .Status : No longer enrolling patients .", "label": "", "metadata": {}, "score": "84.93776"}
{"text": "Variable interval dosing primary endpoint at 1 year . )[ Time Frame : 1 Year ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "85.2047"}
{"text": "Inclusion / Exclusion Criteria : Total lesion size equal to or less than 3,000 microns in greatest diameter ; visual acuity of 15 or more ETDRS letters ; all lesion subtypes .", "label": "", "metadata": {}, "score": "85.36354"}
{"text": "Moreover , the proportion of patients gaining at least 15 letters from baseline was 14.2 % ( 0.3 mg quarterly ) , 17.8 % ( 0.5 mg quarterly ) , and 28.7 % ( 0.3 mg monthly ) .", "label": "", "metadata": {}, "score": "85.782684"}
{"text": "8 This one - year , phase 3b , randomized , double - masked , active - controlled clinical trial involved 353 patients with all types of neovascular AMD .", "label": "", "metadata": {}, "score": "85.82944"}
{"text": "Change From Baseline to Week-6 ( Part A ) Endpoint in Mean Key Symptom Score ( KSS )[ Time Frame : Baseline ( Days -21 to -1 ) and Week 6 ( Days 21 - 42 ) ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "85.84209"}
{"text": "Brief Title ICMJE .Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age - Related Macular Degeneration .Official Title ICMJE .A Phase I Study of the Inhibition of LFA-1 to Intercellular Adhesion Molecule-1 ( ICAM-1 )", "label": "", "metadata": {}, "score": "85.88047"}
{"text": "Only contact the listed numbers .The Lupus Research Institute does not have any jurisdiction over or further involvement with these studies , other than to make people aware that they are being conducted .", "label": "", "metadata": {}, "score": "86.06204"}
{"text": "The primary endpoint was at least a 20 percent improvement in arthritis signs and symptoms ( ACR 20 ) response at week fourteen for combined golimumab groups and individual golimumab dose groups versus placebo .", "label": "", "metadata": {}, "score": "86.179634"}
{"text": "Ability and willingness to return for all scheduled visits and assessments .Study eyes must meet the following criteria for entry into the SAVE trial : .", "label": "", "metadata": {}, "score": "86.32805"}
{"text": "All groups in cohort 1 demonstrated an increase in visual acuity after three consecutive injections ; at month 3 , treatment - na\u00efve patients gained 5.8 letters in the 0.3 mg group and 7.0 letters in the 5.0 mg group .", "label": "", "metadata": {}, "score": "86.393814"}
{"text": "Clear ocular media and adequate papillary dilation to permit good quality stereoscopic fundus photography .Ability to return for all study visits .Exclusion Criteria : .", "label": "", "metadata": {}, "score": "86.59883"}
{"text": "The 12-week ACR50 was 17.4 % in the 20 mg twice daily arm , 13.4 % in the 40 mg once daily arm and 2.9 % in the placebo arm .", "label": "", "metadata": {}, "score": "86.76442"}
{"text": "Both apremilast treatment arms had a significant improvement in the ACR20 outcome versus placebo at 12 weeks .In the 20 mg twice daily arm and the 40 mg once daily arm , 43.5 % and 35.8 % of subjects reached ACR20 , respectively , compared to 11.8 % of subjects in the placebo arm .", "label": "", "metadata": {}, "score": "87.19682"}
{"text": "Serious adverse event ( SAE ) rates were 4.5 % , 2.5 % , and 5.0 % , respectively .December 8 , 2014 .Novartis has reported results of two phase III trials of AIN457 ( secukinumab ) for psoriatic arthritis ( PsA ) .", "label": "", "metadata": {}, "score": "87.254745"}
{"text": "There 's no question of the importance of inhibiting VEGF in the treatment of neovascular age - related macular degeneration .Prospective clinical trials , retrospective studies and our extensive experience with bevacizumab ( Avastin , Genentech ) and ranibizumab ( Lucentis , Genentech ) have confirmed the beneficial effects of anti - VEGF therapies in AMD .", "label": "", "metadata": {}, "score": "87.59972"}
{"text": "Retina specialists should always have the best interests of their patients in mind with the goal of obtaining the best vision possible while minimizing the number of injections .", "label": "", "metadata": {}, "score": "87.661125"}
{"text": "This occurred after the 24-week double blind ( Parts A and B ) phase .In other words , OLE Week 1 corresponded to the week 25 in the study .", "label": "", "metadata": {}, "score": "87.87253"}
{"text": "Study : ANCHOR ( randomized , double - masked , active treatment - controlled study of the efficacy and safety of rhuFAb V2 compared with verteporfin in subjects with predominantly classic subfoveal neovascular AMD ) .", "label": "", "metadata": {}, "score": "88.28182"}
{"text": "Based on these results , Vaxgen planned further development of this drug .Related Medical Areas .This information does not represent a Lupus Research Institute endorsement of any listed study .", "label": "", "metadata": {}, "score": "88.29297"}
{"text": "Ranibizumab intravitreal administration in neovascular AMD patients has been shown to effectively reduce vascular leakage and growth of CNV and to stabilize or improve visual function .", "label": "", "metadata": {}, "score": "88.5726"}
{"text": "NOT A NEW PROBLEM .The first anti - VEGF drug approved by the Food and Drug Administration was pegaptanib sodium ( Macugen , Eyetech ) in December 2004 .", "label": "", "metadata": {}, "score": "88.8659"}
{"text": "Age Related Macular Degeneration .AMD .CNV .Intervention ICMJE .Drug : Efalizumab , Ranibizumab .Study Arm ( s ) .Experimental : I .", "label": "", "metadata": {}, "score": "89.00388"}
{"text": "Data demonstrated statistical significance was achieved for the primary endpoint of ACR 20 at week 16 for patients receiving apremilast 20 mg and 30 mg .", "label": "", "metadata": {}, "score": "89.82074"}
{"text": "If you are presently under the care of a physician for lupus or other conditions , you should not disrupt your current program without discussing it with your doctor(s ) .", "label": "", "metadata": {}, "score": "90.08536"}
{"text": "Status : Ongoing .Purpose : Evaluate the safety and efficacy of ranibizumab ( Lucentis ) compared with verteporfin photodynamic therapy in preventing vision loss associated with age - related macular degeneration .", "label": "", "metadata": {}, "score": "90.48827"}
{"text": "Has an allergy to sodium fluorescein dye .Inability to comply with study or follow - up procedures .Gender .Both .Ages .50 Years and older .", "label": "", "metadata": {}, "score": "90.930084"}
{"text": "Concurrent use of more than two therapies for glaucoma .Concurrent use of systemic anti - VEGF agents .Has active infection in the study eye .", "label": "", "metadata": {}, "score": "92.723854"}
{"text": "Efalizumab could target the adhesion factors that precede angiogenesis and improve the outcome for AMD patients in combination with the anti - VEGF agent , Ranibizumab .", "label": "", "metadata": {}, "score": "93.32991"}
{"text": "THE LESSON .So what does this level one evidence from clinical trial data tell us about the \" ideal \" treatment regimen for neovascular AMD ?", "label": "", "metadata": {}, "score": "94.85334"}
{"text": "Brief Summary .Efalizumab is an immunosuppressive recombinant humanized IgG1 monocolonal antibody ( 150 Kd ) that binds to human CD11a ( 1 ) and is used for the treatment of plaque psoriasis .", "label": "", "metadata": {}, "score": "95.117836"}
{"text": "Fluorescein angiography and autofluorescence will be done at BSL , and Months 6 and 12 .DNA samples for genetic analysis will be collected at baseline .", "label": "", "metadata": {}, "score": "95.174225"}
{"text": "Fibromyalgia syndrome composite responders needed to satisfy the pain composite criteria as well as demonstrate at least a 6-point improvement in their SF-36 physical component summary ( SF-36 PCS ) score .", "label": "", "metadata": {}, "score": "95.272736"}
{"text": "Transport reported positive results from a phase II trial of SoloVir for the treatment of Herpes labialis .This randomized , double blind , placebo - controlled trial , dubbed TPI - H-221 , enrolled two hundred and sixty subjects .", "label": "", "metadata": {}, "score": "95.88931"}
{"text": "Transport plans to conduct additional phase II trials in the next year .VaxGen reported positive results from a phase I trial of rPA102 , the company 's anthrax vaccine candidate .", "label": "", "metadata": {}, "score": "96.06835"}
{"text": "Had treatment with anti - VEGF agents within 30 days prior to BSL .Had treatment with Kenalog within 6 months prior to BSL .Had treatment with Dexamethaosne within 30 days prior to BSL .", "label": "", "metadata": {}, "score": "97.48891"}
{"text": "Choosing to participate in a study is an important personal decision .Talk with your doctor and family members or friends about deciding to join a study .", "label": "", "metadata": {}, "score": "97.678474"}
{"text": "Choosing to participate in a study is an important personal decision .Talk with your doctor and family members or friends about deciding to join a study .", "label": "", "metadata": {}, "score": "97.67848"}
{"text": "Choosing to participate in a study is an important personal decision .Talk with your doctor and family members or friends about deciding to join a study .", "label": "", "metadata": {}, "score": "97.67848"}
{"text": "Talk with your doctor and family members or friends about deciding to join a study .To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .", "label": "", "metadata": {}, "score": "99.453094"}
{"text": "If female , of childbearing potential , and has not used any of the \" acceptable contraceptive methods \" for at least 2 months prior to study entry ; .", "label": "", "metadata": {}, "score": "101.03776"}
{"text": "If female , of childbearing potential , and has not used any of the \" acceptable contraceptive methods \" for at least 2 months prior to study entry ; .", "label": "", "metadata": {}, "score": "101.03776"}
{"text": "Ranibizumab is a recombinant , humanized , Fab fragment of a mouse monoclonal antibody targeted against VEGF .As VEGF binds to cellular receptors , it stimulates angiogenesis and vascular leakage .", "label": "", "metadata": {}, "score": "101.998695"}
{"text": "Enzo is further investigating HGTV43 in phase I / II trials at this time .Tibotec Pharmaceuticals released positive results from a phase IIb trial of TMC125 for the treatment of HIV .", "label": "", "metadata": {}, "score": "104.63986"}
{"text": "Males and females 6 months of age to 17 years of age on the day of enrollment ; .Subject 's parents or legal guardians who have given written consent and the subjects has given assent consent , if applicable ; .", "label": "", "metadata": {}, "score": "110.166794"}
{"text": "Males and females 6 months of age to 17 years of age on the day of enrollment ; .Subject 's parents or legal guardians who have given written consent and the subjects has given assent consent , if applicable ; .", "label": "", "metadata": {}, "score": "110.166794"}
{"text": "Ophthalmology 2009;116:1731 - 9 .Milan Shah , MD , and Philip J. Rosenfeld , MD , PhD , are on the faculty of the Bascom Palmer Eye Institute of the University of Miami .", "label": "", "metadata": {}, "score": "112.11006"}
{"text": "Estimated Enrollment ICMJE .Completion Date .July 2014 .Primary Completion Date .July 2014 ( final data collection date for primary outcome measure ) .", "label": "", "metadata": {}, "score": "115.45157"}
